CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract				
	1a	Identification as a randomised trial in the title	NA	
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see Table 2)	line39-61	abstract
Introduction				
Background and objectives	2a	Scientific background and explanation of rationale	line 68-95	introduction/paragraph2-4
	2b	Specific objectives or hypotheses	line95-101	introduction/paragraph4
Methods				
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	line132-138	method/paragraph12
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA	
Participants	4a	Eligibility criteria for participants	line106-128	method/paragraph6-10
	4b	Settings and locations where the data were collected	line141-165	method/paragraph14-19
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	line132-138	method/paragraph12
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	line141-165	method/paragraph14-19
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA	
Sample size	7a	How sample size was determined	line106-108	method/paragraph6
	7b	When applicable, explanation of any interim analyses and stopping guidelines	line106-108	method/paragraph6
Randomisation:				
Sequence generation	8a	Method used to generate the random allocation sequence	NA	
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	NA	
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	NA	

Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	NA	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	NA	
	11b	If relevant, description of the similarity of interventions	NA	
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	line167-172	methods/paragraph 21
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	ine167-172	methods/paragraph 21
Results				
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	NA	
	13b	For each group, losses and exclusions after randomisation, together with reasons	NA	
Recruitment	14a	Dates defining the periods of recruitment and follow-up	NA	
	14b	Why the trial ended or was stopped	NA	
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	line175-223	Result/paragraph 23-31
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	line175-223	Result/paragraph 23-31
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	line175-223	Result/paragraph 23-31
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	line175-223	Result/paragraph 23-31
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	NA	
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	NA	
Discussion				
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	NA	
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	line293-308	discession/paragrapg37-40
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	line225-290	discession/paragrapg33-36
Other information				
Registration	23	Registration number and name of trial registry	NA	

Protocol	24	Where the full trial protocol can be accessed, if available		
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders		

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

Table 2 Items to include when reporting a randomized trial in a journal or conference abstract

Item	Description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title	Identification of the study as randomized		
Authors *	Contact details for the corresponding author		
Trial design	Description of the trial design (e.g. parallel, cluster, non-inferiority)		
Methods			
Participants	Eligibility criteria for participants and the settings where the data were collected		
Interventions	Interventions intended for each group		
Objective	Specific objective or hypothesis		
Outcome	Clearly defined primary outcome for this report		
Randomization	How participants were allocated to interventions		
Blinding (masking)	Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment		
Results			
Numbers randomized	Number of participants randomized to each group		
Recruitment	Trial status		
Numbers analysed	Number of participants analysed in each group		
Outcome	For the primary outcome, a result for each group and the estimated effect size and its precision		
Harms	Important adverse events or side effects		

Conclusions	General interpretation of the results		
Trial registration	Registration number and name of trial register		
Funding	Source of funding		

** this item is specific to conference abstracts*

From: Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008;5(1):e20

Article Information: http://dx.doi.org/10.21037/apm-20-1074
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.